24/7 Market News Snapshot 20 February, 2025 – Aclarion, Inc. Common Stock (NASDAQ:ACON)

DENVER, Colo., 20 February, 2025 (247marketnews.com) – (NASDAQ:ACON) are discussed in this article.
Aclarion, Inc. (ACON) has seen a remarkable increase in its stock price today, opening at $4.87 and reaching $5.256, representing a notable rise of 16.54% from the previous close of $4.510. This substantial uptick is accompanied by a trading volume of 505.82K, indicating a surge in investor interest and market activity. The combination of heightened trading volumes and a rising share price suggests a potential bullish rally as traders respond to favorable market conditions. Investors are advised to monitor technical indicators for possible resistance and support levels, which could influence subsequent price movements.

In parallel to its stock performance, Aclarion, Inc. is preparing to showcase significant advancements in chronic low back pain management at the 2025 Spine Summit, scheduled for February 21, 2025. Dr. Nicholas Theodore, a prominent orthopedic surgeon and neurosurgery expert, will highlight the company’s cutting-edge decision support tool, NOCISCAN. This innovative platform integrates Magnetic Resonance Spectroscopy (MRS) with augmented intelligence to assist healthcare providers in customizing treatment approaches for patients afflicted by chronic low back pain.

Chronic low back pain is a widespread issue affecting millions, often with traditional imaging methods failing to pinpoint the root causes of pain. NOCISCAN differentiates itself as the first evidence-based Software as a Service (SaaS) solution designed to noninvasively identify painful versus nonpainful discs in the lumbar region. By accurately quantifying chemical biomarkers associated with disc pain, NOCISCAN enhances diagnostic capabilities when implemented alongside conventional imaging tools.

Brent Ness, CEO of Aclarion, underscores the critical role of collaboration with leading medical professionals, asserting that such partnerships are essential for advancing disruptive technologies. The insights shared by Dr. Theodore and Aclarion’s team are pivotal in expanding the accessibility and utility of NOCISCAN.

Attendees at the Spine Summit can anticipate a thorough examination of how NOCISCAN can unveil issues that standard imaging methods might overlook, ultimately promoting more effective and tailored treatment for patients. Aclarion remains committed to revolutionizing the treatment landscape for chronic low back pain, focusing on improving patient outcomes on a global scale.

Related news for (ACON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.